Grail Inc GRAL.OQ GRAL.O is expected to report resultson February 20 for the period ending March 31 2024
LSEG's mean analyst estimate for Grail Inc is for a loss of $7.05 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The average consensus recommendation for the biotechnology & medical research peer group is also "Hold".
Wall Street's median 12-month price target for Grail Inc is $16.00, below its last closing price of $55.02.
This summary was machine generated February 18 at 21:37 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)